Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

The Pharmacogenomics Journal volume 1, pages 204–210 (2001)Cite this article

Abstract

Phenytoin, an anticonvulsant, exhibits nonlinear pharmacokinetics with large interindividual differences. Because of its small therapeutic range with the risk of therapeutic failure or adverse drug effects in susceptible persons, therapeutic drug monitoring is frequently applied. The interindividual differences in dose response can partially be explained by known genetic polymorphisms in the metabolic enzyme CYP2C9 but a large deal of individual variability remains still unexplained. Part of this variability might be accounted for by variable uptake of phenytoin, which is a substrate of p-glycoprotein, encoded by the human MDR1 gene. We evaluated, whether phenytoin plasma levels correlate with a polymorphism in the MDR1 gene, C3435T, which is associated with intestinal PGP activity. Genotyping and analyses of plasma levels of phenytoin and metabolites in 96 healthy Turkish volunteers showed that the MDR1C > T3435 polymorphism affects phenytoin plasma levels (P = 0.064) and the metabolic ratio of p-HPPH vs phenytoin (MDR1*TT genotype, P = 0.026). The MDR1*CC genotype is more common in volunteers with low phenytoin levels (P ≤ 0.001, χ2 test). A combined analysis of variable alleles of CYP2C9, 2C19 and MDR1 revealed that the number of mutant CYP2C9 alleles is a major determinant, the number of MDR1*T alleles further contributes to the prediction of phenytoin plasma levels and CYP2C19*2 does not explain individual variability. The regression equation that fitted the data best included the number of mutant CYP2C9 and MDR*T alleles as predictory variables and explained 15.4% of the variability of phenytoin data (r2 = 0.154, P = 0.0002). Furthermore, analysis of CYP2C9 and MDR1 genotypes in 35 phenytoin-treated patients recruited from therapeutic drug monitoring showed that combined CYP2C9 and MDR1 analysis has some predictive value not only in the controlled settings of a clinical trial, but also in the daily clinical practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Fritz S, Lindner W, Roots I, Frey BM, Küpfer A . Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans J Pharmacol Exp Ther 1987 241: 615–622

    CAS  PubMed  Google Scholar 

  2. Yasumori T, Chen LS, Li QH, Ueda M, Tsuzuki T, Goldstein JA et al. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19 Biochem Pharmacol 1999 57: 1297–1303

    Article  CAS  Google Scholar 

  3. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily Biochem J 1993 289: 533–538

    Article  CAS  Google Scholar 

  4. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA . Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 1994 46: 594–598

    CAS  PubMed  Google Scholar 

  5. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 1994 269: 15419–15422

    CAS  PubMed  Google Scholar 

  6. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin J Pharmacol Exp Ther 1998 284: 356–361

    CAS  PubMed  Google Scholar 

  7. Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H et al. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics Epilepsia 1998 39: 1317–1323

    Article  CAS  Google Scholar 

  8. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy Clin Pharmacol Ther 1997 62: 287–292

    Article  CAS  Google Scholar 

  9. Juliano RL, Ling V . A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta 1976 455: 152–162

    Article  CAS  Google Scholar 

  10. Seelig A . A general pattern for substrate recognition by P-glycoprotein Eur J Biochem 1998 251: 252–261

    Article  CAS  Google Scholar 

  11. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM . Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 1999 39: 361–398

    Article  CAS  Google Scholar 

  12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci U S A 1987 84: 7735–7738

    Article  CAS  Google Scholar 

  13. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I . The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation J Biol Chem 1987 262: 505–508

    CAS  PubMed  Google Scholar 

  14. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR . Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues J Histochem Cytochem 1990 38: 1277–1287

    Article  CAS  Google Scholar 

  15. Fromm MF . P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs J Pharmacol Exp Ther 2000 293: 376–382

    PubMed  Google Scholar 

  16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 2000 97: 3473–3478

    Article  CAS  Google Scholar 

  17. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Öngen Z et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin Br J Clin Pharmacol 1999 48: 409–415

    Article  CAS  Google Scholar 

  18. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population Clin Pharmacol Ther 1999 66: 185–192

    Article  CAS  Google Scholar 

  19. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR . Genetic analysis of the human cytochrome P450 CYP2C9 locus Pharmacogenetics 1996 6: 429–439

    Article  CAS  Google Scholar 

  20. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöquist E . Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Biochem Biophys Res Commun 1999 254: 628–631

    Article  CAS  Google Scholar 

  21. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N . Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication Ther Drug Monit 2000 22: 230–232

    Article  CAS  Google Scholar 

  22. Brockmöller J, Cascorbi I, Henning S, Meisel C, Roots I . Molecular genetics of cancer susceptibility Pharmacology 2000 61: 212–227

    Article  Google Scholar 

  23. Eichelbaum M, Evert B . Influence of pharmacogenetics on drug disposition and response Clin Exp Pharmacol Physiol 1996 23: 983–985

    Article  CAS  Google Scholar 

  24. Bhasker CR, Miners JO, Coulter S, Birkett DJ . Allelic and functional variability of cytochrome P4502C9 Pharmacogenetics 1997 7: 51–58

    Article  CAS  Google Scholar 

  25. Ieiri I, Mamiya K, Urae A, Wada Y, Kimura M, Irie S et al. Stereoselective 4′ hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese Br J Clin Pharmacol 1997 43: 441–445

    Article  CAS  Google Scholar 

  26. Gottesman MM, Pastan I, Ambudkar SV . P-glycoprotein and multidrug resistance Curr Opin Genet Dev 1996 6: 610–617

    Article  CAS  Google Scholar 

  27. Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors Blood 1998 91: 1749–1756

    CAS  PubMed  Google Scholar 

  28. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Pharmacogenetics 2000 10: 583–590

    Article  Google Scholar 

  29. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P . Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J Clin Invest 1995 96: 1698–1705

    Article  CAS  Google Scholar 

  30. Schinkel AH, Wagenaar E, Mol CA, van Deemter L . P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J Clin Invest 1996 97: 2517–2524

    Article  CAS  Google Scholar 

  31. Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A . Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy Pediatr Neurol 1999 21: 731–734

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Parts of this work were supported by grants No. 01EC9408 (Clinical Pharmacogenetics), 01GG9845, and 01GG9848 from the German Ministry for Education and Research.

Author information

Authors and Affiliations

  1. Epidauros Biotechnology AG, Pharmacogenetics Laboratory, Bernried, Germany

    R Kerb, R Schlagenhaufer & U Brinkmann

  2. Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University, Berlin, Germany

    A S Aynacioglu, J Brockmöller, S Bauer & I Roots

  3. Department of Pharmacology, Medical Faculty, Pamukkale University, Denizli, Turkey

    A S Aynacioglu

  4. Institute of Clinical Chemistry, AKH-Wien, University of Vienna, Vienna, Austria

    T Szekeres, A Hamwi & M Fritzer-Szekeres

  5. Institute of Neurology, AKH-Wien, University of Vienna, Vienna, Austria

    C Baumgartner

  6. Department of Pharmacology, Medical Faculty, University of Gaziantep, Turkey

    H Z Öngen & P Güzelbey

Authors
  1. R Kerb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A S Aynacioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Brockmöller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Schlagenhaufer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Szekeres
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Hamwi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Fritzer-Szekeres
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Baumgartner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Z Öngen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Güzelbey
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. I Roots
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. U Brinkmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Kerb.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerb, R., Aynacioglu, A., Brockmöller, J. et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 1, 204–210 (2001). https://doi.org/10.1038/sj.tpj.6500025

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500025

Keywords

This article is cited by

Search

Advanced search

Quick links